Endra Life Sciences Inc Expected To Post A Loss Of 5 Cents A Share: Earnings Preview

ENDRA Life Sciences

11/11/2022 11:25

* ENDRA Life Sciences Inc  NDRA.OQ   NDRA.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 14. 
    * 
    * ​Refinitiv's mean analyst estimate for ENDRA Life Sciences
Inc
is for a loss of 5 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ENDRA Life
Sciences Inc is $4.75​, above​ its last closing price of $0.20.
​​​

This summary was machine generated November 11 at 11:25 GMT. 
All figures in US dollars  unless otherwise stated